Total Long Term Debt (Quarterly) Chart

View Total Long Term Debt (Quarterly) for AMPH.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Total Long Term Debt (Quarterly) Chart
Start Trial

Historical Total Long Term Debt (Quarterly) Data

View and export this data back to 2012. Start Trial.
Date Value
June 30, 2026 679.52M
March 31, 2026 676.67M
December 31, 2025 648.07M
September 30, 2025 648.95M
June 30, 2025 647.62M
March 31, 2025 644.79M
December 31, 2024 643.74M
September 30, 2024 625.64M
June 30, 2024 616.58M
March 31, 2024 623.17M
December 31, 2023 619.74M
September 30, 2023 668.84M
June 30, 2023 525.61M
March 31, 2023 99.03M
December 31, 2022 99.58M
September 30, 2022 100.06M
June 30, 2022 100.61M
March 31, 2022 102.00M
December 31, 2021 101.68M
September 30, 2021 103.27M
June 30, 2021 63.09M
March 31, 2021 60.97M
December 31, 2020 63.91M
September 30, 2020 62.60M
June 30, 2020 61.23M
Date Value
March 31, 2020 63.10M
December 31, 2019 63.45M
September 30, 2019 61.99M
June 30, 2019 64.49M
March 31, 2019 59.73M
December 31, 2018 50.21M
September 30, 2018 51.20M
June 30, 2018 52.59M
March 31, 2018 45.77M
December 31, 2017 47.16M
September 30, 2017 48.44M
June 30, 2017 46.31M
March 31, 2017 36.41M
December 31, 2016 37.72M
September 30, 2016 42.70M
June 30, 2016 42.65M
March 31, 2016 40.27M
December 31, 2015 41.10M
September 30, 2015 46.12M
June 30, 2015 47.43M
March 31, 2015 48.42M
December 31, 2014 43.70M
September 30, 2014 51.35M
June 30, 2014 53.52M
March 31, 2014 41.50M

Total Long Term Debt Definition

Represents a company's total debt maturing for more than 12 months of the reporting period.

Read full definition.

Total Long Term Debt (Quarterly) Range, Past 5 Years

View Total Long Term Debt (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Total Long Term Debt (Quarterly) Benchmarks

View Total Long Term Debt (Quarterly) Benchmarks
Start Trial
Viatris, Inc. 13.51B
Supernus Pharmaceuticals, Inc. 29.43M
Liquidia Corp. 182.90M
ANI Pharmaceuticals, Inc. 610.49M
Corcept Therapeutics, Inc. 7.504M